Form EFFECT Inozyme Pharma, Inc.
Tweet
Share
E-mail| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | July 1, 2025 |
| Accession Number: | 0001193125-25-153591 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ingevity CEO Dave Li and CFO Phillip Platt to speak at 2026 Wells Fargo Industrials & Materials Conference
- Uniserve Announces CEO Gautam Lohia to Speak at BC Tech Member Summit on AI Automation
- Supermicro Announces Proposed $7.0 Billion of Equity and Equity-linked Financing Transactions To Fund AI Orders
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
